[Form 4/A] KESTRA MEDICAL TECHNOLOGIES, LTD. Amended Insider Trading Activity

Rhea-AI Filing Summary

Traci S. Umberger, General Counsel and Chief Administrative Officer and a director, reported an amended Form 4 correcting prior filings to show purchase of 13,500 common shares of Kestra Medical Technologies, Ltd. The transaction occurred on 03/07/2025 at $17.00 per share under the issuer's initial public offering reserved share program. Following the reported purchase, Umberger beneficially owned 134,336 common shares, held directly. The amendment states the shares were inadvertently omitted from prior filings and are now disclosed.

Positive

• Insider purchase disclosed: Purchase of 13,500 shares at $17 increases reported insider ownership to 134,336 shares.
• Amendment improves transparency: The Form 4/A corrects a prior omission, aligning public records with actual transactions.

Negative

• Prior omission: The shares were "inadvertently omitted" from earlier filings, indicating an earlier reporting lapse.

Insights

Financial Analyst

TL;DR: Insider bought 13,500 shares at $17 and amended prior filings to disclose the purchase; ownership now 134,336 shares.

The purchase is a disclosure of insider accumulation under the IPO reserved share program, reported via an amended Form 4. The transaction price of $17 per share and the post-transaction holding of 134,336 shares are clearly stated. The amendment clarifies a prior omission rather than reporting a new trading pattern. For investors, this is a routine corrective filing that provides transparency about insider holdings.

Corporate Governance Expert

TL;DR: Amendment corrects an inadvertent omission; reporting person holds both officer and director roles.

The filing documents a corrective disclosure rather than a change in ownership beyond the original transaction. It identifies the reporting person as a director and officer, which makes accurate disclosure important for compliance with Section 16 obligations. The explanation states the shares were purchased through the IPO reserved share program and omitted unintentionally from earlier filings, and the amended Form 4 remedies that omission.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Umberger Traci S

(Last) (First) (Middle)

C/O KESTRA MEDICAL TECHNOLOGIES, LTD.

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WA 98033

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/21/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/07/2025		P		13,500(1)	A	$17	134,336	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities were purchased in connection with the Issuer's initial public offering reserved share program and were inadvertently omitted from the Reporting Person's prior filings.

Remarks:

General Counsel and Chief Administrative Officer

	/s/ Traci S. Umberger	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Traci S. Umberger report on the amended Form 4 for KMTS?

She reported a purchase of 13,500 common shares on 03/07/2025 at $17.00 per share under the issuer's IPO reserved share program.

How many KMTS shares does Traci Umberger beneficially own after the reported transaction?

She beneficially owns 134,336 common shares following the reported purchase.

Why was an amended Form 4 filed for KMTS by Traci Umberger?

The amendment states the reported securities were purchased in connection with the issuer's IPO reserved share program and were inadvertently omitted from prior filings.

What roles does the reporting person hold at KMTS?

Traci S. Umberger is reported as General Counsel and Chief Administrative Officer and also serves as a director.

What was the transaction date and price for the KMTS purchase disclosed in the amendment?

The transaction date was 03/07/2025 and the price was $17.00 per share.